KC-180-2 Exerts Anti-SCLC Effects via Dual Inhibition of Tubulin Polymerization and Src Signaling-Reference-Cited by-同舟云学术

KC-180-2 Exerts Anti-SCLC Effects via Dual Inhibition of Tubulin Polymerization and Src Signaling

Published:2022-09-01 Issue:36 Volume:7 Page:32164-32175
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Peng Jian¹,Zeng Yisheng¹,Hu Xiaojun¹,Huang Sheng²,Gao Xiaofang¹,Tian Dong¹,Tian Shuting¹,Qiu Lan¹,Liu Jin¹,Dong Renhan²,Zhan Wei²,Qin Chuanjun²,Guang Bing²,Yang Tai¹^ORCID

Affiliation:

1. School of Pharmacy, Chengdu Medical College, No. 783, Xindu Avenue, Xindu District, Chengdu, Sichuan Province 610500, China

2. Chengdu Biobel Biotechnology Co., Ltd., No. 88, Keyuan South Road, New and High-Tech Zone, Chengdu, Sichuan Province 610094, China

Funder

Chengdu Medical College

Graduate Innovation Fund

Sichuan Science and Technology Program

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.2c03408

Reference34 articles.

1. Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis

2. Cancer Statistics, 2021

3. Surgery for small cell lung cancer: When and how

4. First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent updates on c-Src kinase and Src-Abl nonreceptor tyrosine kinases inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

2. Actionable Driver Events in Small Cell Lung Cancer;International Journal of Molecular Sciences;2023-12-20